Concepedia

Author

S Vinayak

University of Alabama at Birmingham

Also Known As

S Vinayak, S. Vinayak, Shenoy Vinayak, Vinayak S

19

Publications

131

Citations

6

H-Index

20

Concepts

All Affiliations

University of Alabama at BirminghamDana-Farber Cancer InstituteCase Western Reserve UniversityTesaro (United States)
SV

About

S Vinayak is an author at University of Alabama at Birmingham specializing in oncology, cancer therapeutics, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

56

2

Pathology

2

2

23

3

Cell Biology

1

1

11

4

Immunology

1

1

13

5

Obstetrics

1

1

20

S Vinayak

×

5

Publications

110

Citations

5

H-Index

YearCitations

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial

Komal Jhaveri, L.D. Eli, Hans Wildiers,

Annals of Oncology

2023

54

Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab

Panagiotis A. Konstantinopoulos, Pamela N. Münster, A. Forero-Torez,

Gynecologic Oncology

2018

20

Abstract PD5-02: Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond <i>BRCA</i>: (TOPACIO/Keynote-162)

S Vinayak, SM Tolaney, Lee S. Schwartzberg,

Cancer Research

2019

13

Dose-finding combination study of niraparib and pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or recurrent platinum-resistant epithelial ovarian cancer (OC) (TOPACIO/Keynote-162)

Panagiotis A. Konstantinopoulos, Jasgit C. Sachdev, Lee S. Schwartzberg,

Annals of Oncology

2017

12

Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)

ML Telli, KC Jensen, Victor Abkevich,

Cancer Research

2012

11

Page 1